Effects of Sacubitril-Valsartan in Heart Failure With Preserved Ejection Fraction in Patients Undergoing Peritoneal Dialysis

Sha Fu, Zhenjian Xu, Baojuan Lin, Junzhe Chen, Qiuyan Huang, Yanchun Xu, Anping Xu, Yangxin Chen, Ying TangFrontiers in Medicine 2021 · DOI

TL;DR

This study investigates the effectiveness and safety of sacubitril-valsartan, a novel heart failure medication, in patients with preserved ejection fraction (HFpEF) who are undergoing peritoneal dialysis (PD). The findings suggest that this treatment significantly improves key heart failure markers and symptoms in this specific patient population, offering a new therapeutic hope where options have been limited.

What Problem Does This Paper Address?

Heart failure with preserved ejection fraction (HFpEF) is a common and serious condition, accounting for about half of all heart failure cases. Unlike heart failure with reduced ejection fraction (HFrEF), effective treatments for HFpEF have been elusive, with diuretics often being the primary intervention. Compounding this challenge, patients with end-stage kidney disease (ESKD) who require peritoneal dialysis (PD) are at a higher risk of heart failure and often have worse outcomes. However, there's a significant lack of data on how novel heart failure medications, like sacubitril-valsartan (an angiotensin receptor-neprilysin inhibitor or ARNI), perform in this vulnerable group of PD patients with HFpEF. This paper aims to fill that knowledge gap by evaluating the efficacy and safety of sacubitril-valsartan in this understudied population.

Methods

This was a retrospective, observational study involving 21 patients with ESKD undergoing PD who also had HFpEF (defined as an ejection fraction of 50% or higher) and elevated NT-proBNP levels. Patients were prescribed sacubitril-valsartan after consultation with a cardiologist, and their clinical and biochemical parameters were assessed before and after treatment, typically over a 3-12 month follow-up period. The study focused on changes in NT-proBNP levels, heart rate, NYHA functional class, and signs/symptoms of heart failure. Safety was evaluated by monitoring for adverse drug reactions, particularly those related to renal function, such as hypotension, hyperkalemia, and angioedema.

Datasets

The study utilized data collected from 21 patients undergoing peritoneal dialysis at Sun Yat-sen Memorial Hospital between January 2018 and December 2019. This data included demographic information, medical history, laboratory values, medication use, clinical parameters (blood pressure, heart rate, signs/symptoms), cardiac structure and function assessed via echocardiography, and cardiac biomarkers (NT-proBNP, CK-MB, troponin I/T). No new datasets or benchmarks were introduced; the study relied on existing patient records.

Key Insights and Ideas

  • A Glimmer of Hope for a Challenging Population: The study provides the first evidence that sacubitril-valsartan can be effective in PD patients with HFpEF, a group with limited treatment options and poor prognoses.
  • Significant Reduction in Key Biomarkers: The dramatic decrease in NT-proBNP, a crucial marker for heart strain, is a strong indicator of the drug's positive impact on cardiac health.
  • Improved Symptoms and Quality of Life: The alleviation of heart failure signs and symptoms, coupled with a notable trend towards improved NYHA classification, suggests a tangible benefit for patients' daily lives.
  • Favorable Safety Profile: Crucially, the treatment was well-tolerated, with no adverse drug reactions observed, even in patients with advanced kidney disease. This is particularly important given the concerns about renal function in this population.
  • Heart Rate Control: The significant reduction in heart rate is another positive finding, contributing to the overall improvement in cardiac function.

Key Results

  • NT-proBNP Reduction: NT-proBNP levels decreased significantly from a median of 9769.0 ng/mL at baseline to 3034.0 ng/mL after treatment (P = 0.002).
  • Heart Rate Reduction: Heart rate also showed a significant decrease from a median of 80.0 bpm to 75.0 bpm (P = 0.031).
  • Symptom Improvement: Signs and symptoms of heart failure were alleviated in 15 out of 21 patients (P = 0.021).
  • NYHA Class Trend: A notable trend towards improvement in NYHA functional class was observed, though not statistically significant, likely due to the small sample size.
  • Safety: No patients experienced adverse drug reactions such as hypotension, hyperkalemia, or angioedema. Renal function (eGFR and serum creatinine) also showed no significant change.

Limitations and Future Work

The authors acknowledge several limitations:

  • Small Sample Size: The study included only 21 patients, which limits the statistical power and generalizability of the findings.
  • Unblinded, Non-Prospective Design: The retrospective and observational nature of the study means it cannot establish causality definitively.
  • Single-Center Study: The findings are specific to one institution.
  • Short Follow-up: While 3-12 months is a reasonable follow-up, longer-term effects are unknown.
  • Volume Load in PD Patients: While efforts were made to exclude patients with overt edema, the inherent volume load in PD patients is a potential confounding factor.

Future work should focus on conducting large-scale, double-blind, controlled studies to definitively confirm the efficacy and safety of sacubitril-valsartan in PD patients with HFpEF. This would provide more robust evidence to guide clinical practice for this challenging patient group.

Summary updated

Abstract

<b>Aims:</b> The effect of the angiotensin receptor-neprilysin inhibitor (ARNI) sacubitril-valsartan in patients with heart failure with preserved ejection fraction (HFpEF) remains unclear, and data on ARNI treatment in peritoneal dialysis (PD) patients are lacking. The present study was designed to assess the efficacy and safety of sacubitril-valsartan in patients with HFpEF undergoing peritoneal dialysis. <b>Methods and Results:</b> End-stage kidney disease (ESKD) patients undergoing PD for 3 months with New York Heart Association (NYHA) class II-IV heart failure, ejection fraction of 50% or higher, and elevated levels of N-terminal pro-B-type natriuretic peptide (NT-proBNP) were assigned to receive sacubitril-valsartan. Patients were followed up regularly after medication treatment. The alterations in clinical and biochemical parameters before and after taking sacubitril-valsartan (generally 50-100 mg b.i.d) were investigated, and safety was also assessed. Twenty-one patients were recruited in this study. Compared with baseline levels, NT-proBNP levels [9769.0 (3093.5-21941.0) vs. 3034.0 (1493.2-6503.0), <i>P</i> = 0.002], and heart rate [80.0 (74.5-90.5) vs. 75.0 (70.3-87.0), <i>P</i> = 0.031] were markedly decreased after treatment with sacubitril-valsartan. Signs and symptoms of heart failure (21/21 vs. 15/21, <i>P</i> = 0.021) were obviously alleviated, NYHA classification and E/e' ratio showed a notable trend of improvement after 3-12 months of follow-up. None of the patients showed adverse drug reactions. <b>Conclusions:</b> The present data suggested that sacubitril-valsartan treatment in patients with HFpEF undergoing PD was effective and safe.
BibTeX
@inproceedings{fu2021effects,
  author = {Sha Fu and Zhenjian Xu and Baojuan Lin and Junzhe Chen and Qiuyan Huang and Yanchun Xu and Anping Xu and Yangxin Chen and Ying Tang},
  title = {{Effects of Sacubitril-Valsartan in Heart Failure With Preserved Ejection Fraction in Patients Undergoing Peritoneal Dialysis}},
  booktitle = {Frontiers in Medicine},
  year = {2021},
  doi = {10.3389/fmed.2021.657067},
}
Figure